Literature DB >> 11920507

Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.

Alexandra M Levine1, Saeed Sadeghi, Byron Espina, Anil Tulpule, Bharat Nathwani.   

Abstract

BACKGROUND: There is recent evidence that the incidence of indolent non-Hodgkin lymphoma (NHL) appears to be increased in persons with the acquired immunodeficiency syndrome (AIDS). The current study was conducted to describe the clinical, immunologic, and pathologic characteristics of indolent B-cell lymphoma in patients infected with the human immunodeficiency virus (HIV).
METHODS: The current report was a retrospective study of 10 cases of indolent NHL identified from the AIDS-Lymphoma Registry at the University of Southern California School of Medicine. These patients were compared with 336 consecutive patients with systemic intermediate/high-grade AIDS-related NHL who were diagnosed and treated at a single institution.
RESULTS: The pathology of the indolent cases included follicular lymphoma (five patients), small lymphocytic lymphoma (two patients), and one case each of mucosa-associated lymphoid tissue (MALT), monocytoid B-cell, and marginal zone lymphoma. When comparing the indolent lymphomas with the intermediate/high-grade AIDS-NHL cases, no differences were observed with regard to demographic characteristics or history of prior opportunistic infection. HIV patients with indolent lymphomas were found to have a significantly higher median CD4+ lymphocyte count compared with patients with intermediate/high-grade NHL (531 /mm3 vs. 90 /mm3) (P < 0.0001). Bone marrow involvement was significantly more common in indolent NHL cases (50%) versus intermediate/high-grade NHL cases (17%) (P = 0.02). The median survival for patients with indolent NHL was significantly longer compared with patients with intermediate/high-grade NHL (66.8 months vs. 7.1 months) (P = 0.007).
CONCLUSIONS: Indolent lymphomas occurring in patients infected with HIV appear to differ from intermediate/high-grade lymphomas with regard to immune status and propensity for bone marrow involvement and prolonged survival. The median survival in the group of HIV-seropositive patients with indolent NHL examined in the current study was found to be comparable to that reported in HIV-negative individuals. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 11920507     DOI: 10.1002/cncr.10368

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis.

Authors:  M Cagliuso; V Conti; S Trasarti; L Lombardi; M Riminucci; M Perez; O Turriziani; F Falasca; M Nanni; A Tafuri; I Mezzaroma
Journal:  Infection       Date:  2012-09-25       Impact factor: 3.553

Review 2.  HIV infection and lymphoma.

Authors:  K L Grogg; R F Miller; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 3.  Immunopathologic differences of Sjögren's syndrome versus sicca syndrome in HCV and HIV infection.

Authors:  Claudio Vitali
Journal:  Arthritis Res Ther       Date:  2011-08-19       Impact factor: 5.156

4.  Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literature.

Authors:  Naoki Shimada; Koichiro Yuji; Nobuhiro Ohno; Tomohiko Koibuchi; Naoki Oyaizu; Kaoru Uchimaru; Arinobu Tojo
Journal:  Clin Case Rep       Date:  2015-04-22

5.  Anaplastic Large Cell Lymphoma Occurring in an HIV-Positive Patient.

Authors:  Philippe Genet; Driss Chaoui; Virginie Masse; Ahmad Al Jijakli; Nina Arakelyan; Laurent Sutton
Journal:  Case Rep Hematol       Date:  2012-12-12

Review 6.  Head and Neck Lymphomas in HIV Patients: a Clinical Perspective.

Authors:  Natsuki Oishi; José Vicente Bagán; Karla Javier; Enrique Zapater
Journal:  Int Arch Otorhinolaryngol       Date:  2017-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.